Pathfinder Medical Appoints Dr. Lorenzo Patrone as CMO

November 25, 2025—Pathfinder Medical, a United Kingdom-based developer of minimally invasive vascular access technologies, announced the appointment of Lorenzo Patrone, MD, as the company’s Chief Medical Officer. Dr. Patrone is a dual-qualified Italian-British interventional radiologist, noted the company.

According to Pathfinder, Dr. Patrone has been collaborating with the company since 2019 as Lead Clinical Consultant. He has played a pivotal role in the development and validation of the company’s ePath catheter system, which is designed for precise, minimally invasive vascular connections.

With Pathfinder, Dr. Patrone performed the first clinical cases using the CE Mark–approved first-generation ePath device to treat lower limb chronic total occlusions. He also led Pathfinder’s preclinical endovascular arteriovenous fistula (endoAVF) studies, including the GLP in-vivo trial, and will now serve as an investigator in the upcoming first-in-human study for wrist-level endoAVF creation, stated the press release.

Pathfinder further noted that Dr. Patrone, who is currently at Azienda USL Toscana Centro in Firenze, Italy, has more than a decade of international experience as a consultant vascular and interventional radiologist. He has published widely on endovascular innovation and served as Assistant Editor for the Journal of Endovascular Therapy. Additionally, he is active in global vascular education such as Vascupedia VIEWS, and is the founder of the FYA congress.

“Creating reliable, minimally invasive vascular access has long been one of the holy grails in interventional medicine,” commented Dr. Patrone in the company’s press release. “Having worked closely with Pathfinder for over 6 years, I’ve seen the transformative potential of its technology and am excited to help guide its journey from concept to clinical adoption.”

Sorin Popa, CEO of Pathfinder Medical, added, “Lorenzo has been a driving force behind the clinical progress of our technology. His extensive endovascular experience, creativity, and passion for improving patient outcomes make him an exceptional addition to our leadership team as we advance toward commercialization.”